Entera Bio (ENTX)
(Delayed Data from NSDQ)
$1.71 USD
0.00 (0.00%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.71 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ENTX 1.71 0.00(0.00%)
Will ENTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ENTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ENTX
All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy
AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
ENTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Has Entera Bio (ENTX) Outpaced Other Medical Stocks This Year?
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
Other News for ENTX
Entera Bio to Participate in Upcoming Investor and Scientific Conferences
ENTX Stock Earnings: Entera Bio Meets EPS for Q2 2024
Entera Bio Receives Strong Buy Rating Amid Anticipated FDA Ruling and Pipeline Progress
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
Entera Bio Clarifies Non-Binding Information Disclosure